NICE backs Lilly’s Emgality for migraine, adding pressure on NovartisUK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for Share XNICE backs Lilly’s Emgality for migraine, adding pressure on Novartishttps://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/
Novartis’ Aimovig tops topiramate in migraine face-offNovartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to Share XNovartis’ Aimovig tops topiramate in migraine face-offhttps://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/
After rejection, NICE agrees to look again at migraine drug AimovigThe UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS Share XAfter rejection, NICE agrees to look again at migraine drug Aimovighttps://pharmaphorum.com/news/nice-migraine-aimovig/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
Cancer update buoys Amgen despite Q2 sales fallAmgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but Share XCancer update buoys Amgen despite Q2 sales fallhttps://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/
Scotland backs Aimovig for migraine after NICE says noPeople suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig Share XScotland backs Aimovig for migraine after NICE says nohttps://pharmaphorum.com/news/scotland-backs-aimovig-for-migraine-after-nice-says-no/
NICE rejects Novartis’ migraine prevention drug AimovigSome migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are Share XNICE rejects Novartis’ migraine prevention drug Aimovighttps://pharmaphorum.com/news/nice-rejects-novartis-migraine-prevention-drug-aimovig/
Breakthrough migraine prevention treatment approved in EuropeNovartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine Share XBreakthrough migraine prevention treatment approved in Europehttps://pharmaphorum.com/news/breakthrough-migraine-prevention-treatment-approved-in-europe/
Migraine prevention drug Aimovig poised for EU approvalThe first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval. The Share XMigraine prevention drug Aimovig poised for EU approvalhttps://pharmaphorum.com/news/migraine-prevention-aimovig-eu-approval/
